RxDoctor Payments Data

Augustine Romano, MD

Neurology · Rocky Point, NYNPI 1255486353

Payments from drug & device makers

$24,702in general payments, 2019–2025

Across 1,254 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • UCB, Inc.$2K
  • Biogen$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Lundbeck LLC$1K
  • SK Life Science, Inc.$997
  • plus $14K from 54 others

What the payments were for

  • Speaking & faculty fees$2021%
  • Food & beverage$24,47199%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)242$4,379
UCB, Inc.84$1,688
Biogen83$1,419
Teva Pharmaceuticals USA, Inc.78$1,261
Lundbeck LLC60$1,140
SK Life Science, Inc.26$997
Amgen(2 entities)49$945
Novartis45$934
Sunovion Pharmaceuticals Inc.33$823
Lilly USA, LLC37$809
Amneal Pharmaceuticals LLC34$710
Pfizer40$703
Neurelis, Inc.22$522
Acadia Pharmaceuticals Inc25$500
Acorda Therapeutics, Inc27$455
Neurocrine Biosciences, Inc.13$445
Argenx US, Inc.19$400
EMD Serono, Inc.16$368
Supernus Pharmaceuticals, Inc.23$345
Upsher-smith Laboratories LLC17$342
Grifols USA, LLC18$332
Axsome Therapeutics, Inc.10$331
Kyowa Kirin, Inc.12$307
AstraZeneca12$256
Adamas Pharmaceuticals, Inc.13$255
Biohaven Pharmaceutical Holding Company Ltd.12$236
Arbor Pharmaceuticals, Inc.22$218
Medtronic(2 entities)5$213
Biohaven Pharmaceuticals, Inc.11$204
Eisai Inc.11$193
Merz Pharmaceuticals, LLC6$177
Almatica Pharma LLC8$162
Otsuka America Pharmaceutical, Inc.7$160
Idorsia Pharmaceuticals US Inc7$152
Azurity Pharmaceuticals, Inc.9$144
Sanofi8$142
MDD US Operations, LLC7$141
Sumitomo Pharma America, Inc.6$128
Scilex Pharmaceuticals Inc.6$121
CSL Behring6$120
Jazz Pharmaceuticals Inc.4$110
GE HealthCare8$98
Takeda Pharmaceuticals U.S.A., Inc.4$94
Genentech USA, Inc.6$88
Bristol Myers Squibb5$84
Livanova USA, Inc.4$77
ITF Therapeutics LLC3$76
Avion Pharmaceuticals4$73
Avanir Pharmaceuticals, Inc.4$73
Assertio Therapeutics, Inc.5$67
Abbott1$66
Greenwich Biosciences, Inc.3$60
E.r. Squibb & Sons, L.L.C.3$58
Bausch Health US, LLC3$52
Tanabe Pharma America, Inc.2$44
Merz North America, Inc.3$44
Biodelivery Sciences International, Inc.3$43
Impel Pharmaceuticals LLC2$41
Akcea Therapeutics, Inc.3$40
Impel Pharmaceuticals Inc.2$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,702 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$211,956
Medicare patients
535
Services billed
8,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate11$98,786
AptiomEslicarbazepine Acetate39$77,371
RytaryCarbidopa/Levodopa59$70,260
Nurtec OdtRimegepant Sulfate41$49,143
EpidiolexCannabidiol (Cbd)12$34,133
QuliptaAtogepant13$21,776
UbrelvyUbrogepant20$20,656
Topiramate ErTopiramate13$15,577
Gabapentin ErGabapentin15$12,959
XcopriCenobamate12$12,501
Galantamine ErGalantamine Hbr94$12,465
Ajovy AutoinjectorFremanezumab-Vfrm15$10,087
Donepezil Hcl219$3,818
Oxcarbazepine36$3,752
Baclofen72$3,733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$1,419$98,78611 claims
Sunovion Pharmaceuticals Inc.Aptiom$823$77,37139 claims
Amneal Pharmaceuticals LLCRytary$710$70,26059 claims
PfizerNurtec Odt$703$49,14341 claims
AbbVieQulipta, Ubrelvy$4,379$42,43233 claims
SK Life Science, Inc.Xcopri$997$12,50112 claims
Upsher-smith Laboratories LLCTopiramate$342$85257 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.

Other neurology in Rocky Point

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →